Stock AXIM AXIM BIOTECHNOLOGIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News AXIM Biotechnologies, Inc.

Equities

AXIM

US05463V1008

Market Closed - OTC Markets
Other stock markets
 15:11:46 2024-04-26 EDT 		5-day change 1st Jan Change
0.0137 USD +11.84% Intraday chart for AXIM Biotechnologies, Inc. -8.67% -27.89%
04-16 AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
03-15 AXIM Biotechnologies, Inc. announced that it has received $0.814555 million in funding CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
AXIM Biotechnologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
VIDEO: AXIM Biotechnologies CEO Presents at Benzinga Virtual Healthcare Summit 2024
AQ
AXIM Biotechnologies, Inc. announced that it has received $0.814555 million in funding
CI
AXIM® Biotechnologies’ Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
AQ
AXIM Biotechnologies, Inc Tear Based Testing Platform Continues to Gain Traction After Successful Clinical Validation
CI
AXIM Biotechnologies, Inc. announced that it expects to receive $0.75 million in funding from Medical Marijuana, Inc.
CI
AXIM® Biotechnologies Partners With Leading Diagnostic Manufacturer Auer Precision to Scale Assay Production
AQ
AXIM Biotechnologies, Inc. Partners With Auer Precision to Scale Assay Production
CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
AXIM® Biotechnologies Develops First Non-Invasive, Rapid, Point-of-Care, Diagnostic Test for Parkinson’s Disease
BU
AXIM Biotechnologies Develops First Non-Invasive, Rapid, Point-Of-Care, Diagnostic Test for Parkinson's Disease
CI
AXIM Biotechnologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
AXIM® Biotechnologies Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
BU
AXIM Biotechnologies, Inc. Receives Notice of U.S. Patent Allowance for Three Separate Patents Including Its Rapid Point of Care Neutralizing Antibody Test
CI
AXIM Biotechnologies - Optometric Management, Perform a Pre-Fit Ocular Surface Evaluation
AQ
AXIM® Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
AQ
AXIM Biotechnologies Starts Shipping Revenue Generating IgE Diagnostic Validation Assays to Customers Nationwide
CI
AXIM Biotechnologies, Inc. announced that it has received $20 million in funding
CI
AXIM Biotechnologies Announces Over 40 Initial Clinic Commitments for Its Full Diagnostic Assay Platform Launch
AQ
AXIM® Biotechnologies Appoints Kurt Phinney as Chief Operating Officer to Drive Scaling and Optimization of Manufacturing Unit
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. AXIM Stock
  4. News AXIM Biotechnologies, Inc.